Last reviewed · How we verify

Anthim — Competitive Intelligence Brief

Anthim (OBILTOXAXIMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthrax Protective Antigen-directed Antibody [EPC]. Area: Other.

marketed Anthrax Protective Antigen-directed Antibody [EPC] Other Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Anthim (OBILTOXAXIMAB) — Elusys Therapeutics Inc. Anthim works by binding to the protective antigen of anthrax toxin, neutralizing its effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Anthim TARGET OBILTOXAXIMAB Elusys Therapeutics Inc marketed Anthrax Protective Antigen-directed Antibody [EPC] 2016-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthrax Protective Antigen-directed Antibody [EPC] class)

  1. Elusys Therapeutics Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anthim — Competitive Intelligence Brief. https://druglandscape.com/ci/obiltoxaximab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: